Related references
Note: Only part of the references are listed.Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan H. Fowler et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells
Kamira Maharaj et al.
BLOOD ADVANCES (2020)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew Lunning et al.
BLOOD (2019)
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study
Matthew S. Davids et al.
LANCET HAEMATOLOGY (2019)
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Howard A. Burris et al.
LANCET ONCOLOGY (2018)
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Ian W. Flinn et al.
BLOOD (2018)
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies
Changchun Deng et al.
BLOOD (2017)
PI3K-selective and PI3K/-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma
Benjamin L. Lampson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Benjamin L. Lampson et al.
BLOOD (2016)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
David G. Winkler et al.
CHEMISTRY & BIOLOGY (2013)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
The PI3K Isoforms p110α and p110δ Are Essential for Pre-B Cell Receptor Signaling and B Cell Development
Faruk Ramadani et al.
SCIENCE SIGNALING (2010)
Phosphoinositide 3-Kinase p110δ Regulates Natural Antibody Production, Marginal Zone and B-1 B Cell Function, and Autoantibody Responses
Caylib A. Durand et al.
JOURNAL OF IMMUNOLOGY (2009)
Signalling by PI3K isoforms: insights from gene-targeted mice
B Vanhaesebroeck et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
Cutting edge:: Differential roles for phosphoinositide 3-kinases, p110γ and p110δ, in lymphocyte chemotaxis and homing
K Reif et al.
JOURNAL OF IMMUNOLOGY (2004)
A crucial role for the p110δ subunit of phosphatidylinositol 3-kinase in B cell development and activation
E Clayton et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Share Paper
